Could Trump’s NAFTA Renegotiation Hit Canadian Drug Price Controls?
Thanks to forthcoming NAFTA renegotiations, the US could put Canada under pressure to rethink its plans to curb excessive pricing.
You may also be interested in...
As work on policy development and executive orders continues, critics implore Trump to return to his "getting away with murder" roots.
US pharmaceutical industry association PhRMA has laid out what it thinks should be priorities in the upcoming renegotiation of the North American Free Trade Agreement. It wants pricing and reimbursement systems that reward innovation and improved enforcement of patentability standards.
Canadian authorities are consulting on potential new measures for curbing high drug prices. One of these would extend the list of countries it uses for international price comparisons.